San Diego-based mostly Viking Therapeutics marked itself as a serious competitor inside the weight loss drug marketplace in February following revealing promising knowledge from the mid-phase trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when given being a weekly injection As well as in March